Mizuho Securities Remains a Buy on Assembly Biosciences (ASMB)


Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences (ASMB) today and set a price target of $13.00. The company’s shares closed last Thursday at $5.94, close to its 52-week low of $4.78.

According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -5.7% and a 46.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Wave Life Sciences.

Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.84 and a one-year low of $4.78. Currently, Assembly Biosciences has an average volume of 1.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts